Sonidegib preplanned subgroups analyses of objective response rates: Final 42-month results from the BOLT study von Dummer, R.

Volltext

Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity: clinical outcomes in advanced melanoma von Jansen, Y.J.L., Rozeman, E.A., Mason, R., Goldinger, S.M., Geukes Foppen, M.H., Hoejberg, L., Schmidt, H., van Thienen, J.V., Haanen, J.B.A.G., Tiainen, L., Svane, I.M., Mäkelä, S., Seremet, T., Arance, A., Dummer, R., Bastholt, L., Nyakas, M., Straume, O., Menzies, A.M., Long, G.V., Atkinson, V., Blank, C.U., Neyns, B.

Volltext

EANO–ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with brain metastasis from solid tumours von Le Rhun, E., Guckenberger, M., Smits, M., Dummer, R., Bachelot, T., Sahm, F., Galldiks, N., de Azambuja, E., Berghoff, A.S., Metellus, P., Peters, S., Hong, Y.-K., Winkler, F., Schadendorf, D., van den Bent, M., Seoane, J., Stahel, R., Minniti, G., Wesseling, P., Weller, M., Preusser, M.

Volltext

Transient MEK inhibitor-associated retinopathy in metastatic melanoma von Urner-Bloch, U., Urner, M., Stieger, P., Galliker, N., Winterton, N., Zubel, A., Moutouh-de Parseval, L., Dummer, R., Goldinger, S.M.

Volltext

Long‐term efficacy and safety of sonidegib in patients with advanced basal cell carcinoma: 42‐month analysis of the phase II randomized, double‐blind BOLT study von Dummer, R., Guminksi, A., Gutzmer, R., Lear, J.T., Lewis, K.D., Chang, A.L.S., Combemale, P., Dirix, L., Kaatz, M., Kudchadkar, R., Loquai, C., Plummer, R., Schulze, H.‐J., Stratigos, A.J., Trefzer, U., Squittieri, N., Migden, M.R.

Volltext

Neoadjuvant talimogene laherparepvec plus surgery versus surgery alone for resectable stage IIIB–IVM1a melanoma: a randomized, open-label, phase 2 trial von Dummer, R., Gyorki, D. E., Hyngstrom, J., Berger, A. C., Conry, R., Demidov, L., Sharma, A., Treichel, S. A., Radcliffe, H., Gorski, K. S., Anderson, A., Chan, E., Faries, M., Ross, M. I.

Volltext

Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up von Dummer, R, Hauschild, A, Guggenheim, M, Keilholz, U, Pentheroudakis, G

Volltext

Vismodegib in patients with advanced basal cell carcinoma: Primary analysis of STEVIE, an international, open-label trial von Basset-Séguin, N., Hauschild, A., Kunstfeld, R., Grob, J., Dréno, B., Mortier, L., Ascierto, P.A., Licitra, L., Dutriaux, C., Thomas, L., Meyer, N., Guillot, B., Dummer, R., Arenberger, P., Fife, K., Raimundo, A., Dika, E., Dimier, N., Fittipaldo, A., Xynos, I., Hansson, J.

Volltext

Sonidegib and vismodegib in the treatment of patients with locally advanced basal cell carcinoma: a joint expert opinion von Dummer, R., Ascierto, P.A., Basset‐Seguin, N., Dréno, B., Garbe, C., Gutzmer, R., Hauschild, A., Krattinger, R., Lear, J.T., Malvehy, J., Schadendorf, D., Grob, J.J.

Volltext

How to break resistance to hedgehog inhibitors in advanced basal cell carcinoma? von Ramelyte, E., Restivo, G., Imhof, L., Nägeli, M.C., Dummer, R.

Volltext

ESMO consensus conference recommendations on the management of metastatic melanoma: under the auspices of the ESMO Guidelines Committee von Keilholz, U., Ascierto, P.A., Dummer, R., Robert, C., Lorigan, P., van Akkooi, A., Arance, A., Blank, C.U., Chiarion Sileni, V., Donia, M., Faries, M.B., Gaudy-Marqueste, C., Gogas, H., Grob, J.J., Guckenberger, M., Haanen, J., Hayes, A.J., Hoeller, C., Lebbé, C., Lugowska, I., Mandalà, M., Márquez-Rodas, I., Nathan, P., Neyns, B., Olofsson Bagge, R., Puig, S., Rutkowski, P., Schilling, B., Sondak, V.K., Tawbi, H., Testori, A., Michielin, O.

Volltext

Long‐term efficacy and safety of sonidegib in patients with locally advanced and metastatic basal cell carcinoma: 30‐month analysis of the randomized phase 2 BOLT study von Lear, J.T., Migden, M.R., Lewis, K.D., Chang, A.L.S., Guminski, A., Gutzmer, R., Dirix, L., Combemale, P., Stratigos, A., Plummer, R., Castro, H., Yi, T., Mone, M., Zhou, J., Trefzer, U., Kaatz, M., Loquai, C., Kudchadkar, R., Sellami, D., Dummer, R.

Volltext

Challenges in diagnosis and management of neutropenia upon exposure to immune-checkpoint inhibitors: meta-analysis of a rare immune-related adverse side effect von Boegeholz, J, Brueggen, C S, Pauli, C, Dimitriou, F, Haralambieva, E, Dummer, R, Manz, M G, Widmer, C C

Volltext

Histiocytosis – cutaneous manifestations of hematopoietic neoplasm and non‐neoplastic histiocytic proliferations von Luder, C.M., Nordmann, T.M., Ramelyte, E., Mühleisen, B., Kerl, K., Guenova, E., Dummer, R.

Volltext

Efficacy and safety of nilotinib in patients with KIT-mutated metastatic or inoperable melanoma: final results from the global, single-arm, phase II TEAM trial von Guo, J., Carvajal, R.D., Dummer, R., Hauschild, A., Daud, A., Bastian, B.C., Markovic, S.N., Queirolo, P., Arance, A., Berking, C., Camargo, V., Herchenhorn, D., Petrella, T.M., Schadendorf, D., Sharfman, W., Testori, A., Novick, S., Hertle, S., Nourry, C., Chen, Q., Hodi, F.S.

Volltext

ESMO consensus conference recommendations on the management of locoregional melanoma: under the auspices of the ESMO Guidelines Committee von Michielin, O., van Akkooi, A., Lorigan, P., Ascierto, P.A., Dummer, R., Robert, C., Arance, A., Blank, C.U., Chiarion Sileni, V., Donia, M., Faries, M.B., Gaudy-Marqueste, C., Gogas, H., Grob, J.J., Guckenberger, M., Haanen, J., Hayes, A.J., Hoeller, C., Lebbé, C., Lugowska, I., Mandalà, M., Márquez-Rodas, I., Nathan, P., Neyns, B., Olofsson Bagge, R., Puig, S., Rutkowski, P., Schilling, B., Sondak, V.K., Tawbi, H., Testori, A., Keilholz, U.

Volltext

Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up von Dummer, R., Hauschild, A., Lindenblatt, N., Pentheroudakis, G., Keilholz, U.

Volltext

Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up von Michielin, O., van Akkooi, A.C.J., Ascierto, P.A., Dummer, R., Keilholz, U.

Volltext

Light‐based therapies and scar sarcoidosis von Walther, M., Dummer, R., Imhof, L.

Volltext

Systemic inflammatory reaction syndrome during combined kinase inhibitor therapy following anti-PD-1 therapy for melanoma von Urosevic-Maiwald, M., Mangana, J., Dummer, R.

Volltext